A month after losing its lead program, Unity Biotechnology cuts 30% of staff in restructuring
Unity Biotechnology lost its lead anti-aging program last month after a Phase II flop. Now, 30% of its staff will be cut as the company restructures to focus on ophthalmology and neurology.
The cuts will leave Unity with 75 full-time employees by the end of the year. Funded by celebrities, Unity has been focused on clearing senescent cells to reduce the symptoms of aging.
